Answers are grounded in this paper and cite their sources.
Systematic review identifies challenges and recommendations for improving access to NCD medicines in low-resource settings.
Challenges across all six dimensions of access significantly affect access to NCD medicines. These challenges were exacerbated during the COVID-19 pandemic. Access recommendations include (1) improved evidence-based forecasting to reduce stockouts through investments in data infrastructure, innovative LMIC-specific forecasting tools and pooled procurement; (2) increased use of quality-assured generic medicines through international non-proprietary name prescribing, regulation of originator brand promotion and generic substitution; (3) improved quality of NCD medicines through stringent regulatory requirements and national and supranational pharmacovigilance systems; and (4) expansion of NCD medicine financing through universal health coverage.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: